vs
Side-by-side financial comparison of Bio-Techne (TECH) and VILLAGE SUPER MARKET INC (VLGEA). Click either name above to swap in a different company.
VILLAGE SUPER MARKET INC is the larger business by last-quarter revenue ($582.6M vs $311.4M, roughly 1.9× Bio-Techne). Bio-Techne runs the higher net margin — 16.4% vs 2.1%, a 14.3% gap on every dollar of revenue. On growth, VILLAGE SUPER MARKET INC posted the faster year-over-year revenue change (4.5% vs -1.5%). Over the past eight quarters, Bio-Techne's revenue compounded faster (1.3% CAGR vs 0.6%).
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
A supermarket is a self-service shop offering a wide variety of food, beverages and household products, organized into sections under one roof. The supermarket retail format first appeared around 1930 in the United States as the culmination of almost two decades of retail innovations to the grocery store, and began to spread to other countries after extensive worldwide publicity in 1956. In everyday American English usage, "grocery store" is often used interchangeably with "supermarket", whil...
TECH vs VLGEA — Head-to-Head
Income Statement — Q3 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $311.4M | $582.6M |
| Net Profit | $51.0M | $12.0M |
| Gross Margin | 66.9% | 28.3% |
| Operating Margin | 24.2% | 2.6% |
| Net Margin | 16.4% | 2.1% |
| Revenue YoY | -1.5% | 4.5% |
| Net Profit YoY | 126.0% | -6.3% |
| EPS (diluted) | $0.32 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $311.4M | — | ||
| Q4 25 | $295.9M | $582.6M | ||
| Q3 25 | — | $599.7M | ||
| Q2 25 | $317.0M | $563.7M | ||
| Q1 25 | $316.2M | $599.7M | ||
| Q4 24 | $297.0M | $557.7M | ||
| Q3 24 | $289.5M | $578.2M | ||
| Q2 24 | $306.1M | $546.4M |
| Q1 26 | $51.0M | — | ||
| Q4 25 | $38.0M | $12.0M | ||
| Q3 25 | — | $15.5M | ||
| Q2 25 | $-17.7M | $11.2M | ||
| Q1 25 | $22.6M | $16.9M | ||
| Q4 24 | $34.9M | $12.8M | ||
| Q3 24 | $33.6M | $15.4M | ||
| Q2 24 | $40.6M | $9.0M |
| Q1 26 | 66.9% | — | ||
| Q4 25 | 64.6% | 28.3% | ||
| Q3 25 | — | 28.2% | ||
| Q2 25 | 62.7% | 28.8% | ||
| Q1 25 | 67.9% | 28.4% | ||
| Q4 24 | 65.3% | 29.0% | ||
| Q3 24 | 63.2% | 29.3% | ||
| Q2 24 | 66.4% | 28.5% |
| Q1 26 | 24.2% | — | ||
| Q4 25 | 18.4% | 2.6% | ||
| Q3 25 | — | 3.4% | ||
| Q2 25 | -7.5% | 2.4% | ||
| Q1 25 | 12.2% | 3.7% | ||
| Q4 24 | 16.0% | 2.9% | ||
| Q3 24 | 13.8% | 3.3% | ||
| Q2 24 | 15.0% | 1.9% |
| Q1 26 | 16.4% | — | ||
| Q4 25 | 12.8% | 2.1% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | -5.6% | 2.0% | ||
| Q1 25 | 7.1% | 2.8% | ||
| Q4 24 | 11.7% | 2.3% | ||
| Q3 24 | 11.6% | 2.7% | ||
| Q2 24 | 13.3% | 1.6% |
| Q1 26 | $0.32 | — | ||
| Q4 25 | $0.24 | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-0.11 | — | ||
| Q1 25 | $0.14 | — | ||
| Q4 24 | $0.22 | — | ||
| Q3 24 | $0.21 | — | ||
| Q2 24 | $0.26 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $209.8M | $117.7M |
| Total DebtLower is stronger | — | $55.7M |
| Stockholders' EquityBook value | $2.1B | $501.1M |
| Total Assets | $2.6B | $1.0B |
| Debt / EquityLower = less leverage | — | 0.11× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $209.8M | — | ||
| Q4 25 | $172.9M | $117.7M | ||
| Q3 25 | — | $110.7M | ||
| Q2 25 | $162.2M | $115.4M | ||
| Q1 25 | $140.7M | $133.9M | ||
| Q4 24 | $177.5M | $117.2M | ||
| Q3 24 | $187.5M | $117.3M | ||
| Q2 24 | $152.9M | $113.9M |
| Q1 26 | — | — | ||
| Q4 25 | $260.0M | $55.7M | ||
| Q3 25 | — | $58.0M | ||
| Q2 25 | $346.0M | $60.3M | ||
| Q1 25 | $330.0M | $62.7M | ||
| Q4 24 | $300.0M | $69.9M | ||
| Q3 24 | $300.0M | $72.2M | ||
| Q2 24 | $319.0M | $74.6M |
| Q1 26 | $2.1B | — | ||
| Q4 25 | $2.0B | $501.1M | ||
| Q3 25 | — | $492.0M | ||
| Q2 25 | $1.9B | $479.7M | ||
| Q1 25 | $2.0B | $472.0M | ||
| Q4 24 | $2.1B | $457.5M | ||
| Q3 24 | $2.1B | $447.6M | ||
| Q2 24 | $2.1B | $436.2M |
| Q1 26 | $2.6B | — | ||
| Q4 25 | $2.5B | $1.0B | ||
| Q3 25 | — | $1.0B | ||
| Q2 25 | $2.6B | $995.6M | ||
| Q1 25 | $2.6B | $1.0B | ||
| Q4 24 | $2.7B | $990.3M | ||
| Q3 24 | $2.7B | $981.7M | ||
| Q2 24 | $2.7B | $970.2M |
| Q1 26 | — | — | ||
| Q4 25 | 0.13× | 0.11× | ||
| Q3 25 | — | 0.12× | ||
| Q2 25 | 0.18× | 0.13× | ||
| Q1 25 | 0.16× | 0.13× | ||
| Q4 24 | 0.14× | 0.15× | ||
| Q3 24 | 0.14× | 0.16× | ||
| Q2 24 | 0.15× | 0.17× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $19.7M |
| Free Cash FlowOCF − Capex | — | $10.7M |
| FCF MarginFCF / Revenue | — | 1.8% |
| Capex IntensityCapex / Revenue | — | 1.5% |
| Cash ConversionOCF / Net Profit | — | 1.64× |
| TTM Free Cash FlowTrailing 4 quarters | — | $36.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $19.7M | ||
| Q3 25 | — | $21.7M | ||
| Q2 25 | $98.2M | $10.6M | ||
| Q1 25 | $41.1M | $40.8M | ||
| Q4 24 | $84.3M | $20.2M | ||
| Q3 24 | $63.9M | $22.8M | ||
| Q2 24 | $75.5M | $9.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | $10.7M | ||
| Q3 25 | — | $11.6M | ||
| Q2 25 | $93.3M | $-10.6M | ||
| Q1 25 | $31.0M | $24.9M | ||
| Q4 24 | $77.5M | $8.5M | ||
| Q3 24 | $54.7M | $13.8M | ||
| Q2 24 | $57.5M | $-10.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.8% | ||
| Q3 25 | — | 1.9% | ||
| Q2 25 | 29.4% | -1.9% | ||
| Q1 25 | 9.8% | 4.2% | ||
| Q4 24 | 26.1% | 1.5% | ||
| Q3 24 | 18.9% | 2.4% | ||
| Q2 24 | 18.8% | -1.8% |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.5% | ||
| Q3 25 | — | 1.7% | ||
| Q2 25 | 1.5% | 3.8% | ||
| Q1 25 | 3.2% | 2.6% | ||
| Q4 24 | 2.3% | 2.1% | ||
| Q3 24 | 3.2% | 1.6% | ||
| Q2 24 | 5.9% | 3.5% |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.64× | ||
| Q3 25 | — | 1.40× | ||
| Q2 25 | — | 0.95× | ||
| Q1 25 | 1.82× | 2.41× | ||
| Q4 24 | 2.42× | 1.58× | ||
| Q3 24 | 1.90× | 1.48× | ||
| Q2 24 | 1.86× | 1.04× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
TECH
| Protein Sciences segment revenue | $226.2M | 73% |
| Diagnostics and Spatial Biology segment revenue | $85.6M | 27% |
| Other revenue (1) | $5.4M | 2% |
VLGEA
| Center Store | $342.7M | 59% |
| Fresh | $211.0M | 36% |
| Pharmacy | $26.3M | 5% |
| Other Product | $2.6M | 0% |
